Supplement Dispensary

Protocol overview: Sleep support starts by distinguishing a busy mind at bedtime, difficulty falling asleep, nighttime awakenings, and ongoing sleep disruption. The proposed components differ according to the main concern and the need for short-term versus maintenance support.

• Tro+ Calm: A component of the winding-down pathway for a noisy mind and persistent overactivation.
• Tro Zzz: A component of the pathway for milder sleep difficulties and longer-term maintenance.
• Tro+ Somna: A component of the pathway for more severe sleep disruption or short-term rescue, with formulations that may include melatonin.
• Tro+ Mune: An optional component in the sleep-and-recovery framework when concerns remain unresolved.

Clinical approach: Evaluate medical, psychiatric, behavioral, circadian, and medication-related causes of poor sleep. Any product changes require individualized reassessment, with attention to morning grogginess and daytime functioning. More products do not necessarily mean better sleep.

Discuss existing sleep medicines, alcohol use, and other sedating products with your clinician. Do not combine these products or replace prescribed treatment on your own.

Protocol overview: Anxiety can involve overactivation, exhaustion, disrupted sleep, or a combination. This framework organizes proposed support around the dominant pattern rather than treating every experience of anxiety the same way.

• Overactivated or reactive: Rumination, irritability, sensitivity to stimulation, and difficulty switching off. Tro+ Calm is the proposed component in this pathway.
• “Wired but tired”: Anxiety with fatigue, energy crashes, or feeling worse after calming products. The proposed pathway centers on Tro+ Blue, with Tro+ Calm or Tro+ Somna as possible additions according to remaining concerns.
• Sleep-linked anxiety: Anxiety that worsens after poor sleep or early awakening. The proposed pathway centers on Tro+ Somna, with Tro+ Calm or Tro+ Blue considered for ongoing daytime concerns or low energy.

Clinical approach: Review triggers, sleep quality, fatigue, medications, and any history of activation. Reassess the explanation if symptoms worsen or remain unstable. These patterns are not diagnoses.

Core components: The proposed framework includes Tro+ Blue or Just Blue as methylene-blue options, alongside Tro+ Mune. The framework also includes a Tro+ Mune-only pathway for people who avoid or do not tolerate methylene blue.

Optional components: Tro+ Calm is included in the framework for anxiety, irritability, emotional regulation, and difficulty settling or transitioning. Tro Zzz is included in the sleep-support pathway.

Nutritional considerations: Metabolic-support considerations include magnesium, creatine, CoQ10, acetyl-L-carnitine, B vitamins, riboflavin, and PQQ. Antioxidant options include vitamin C, NAC, glutathione, alpha-lipoic acid, selenium, vitamin E, and polyphenols. These are potential discussion topics, not a recommendation to take the entire list.

Daily foundations: Consistent sleep, morning light, physical activity, outdoor time, breathing practices, and behavioral and educational supports.

Clinical review: Monitor sleep, restlessness, irritability, gastrointestinal symptoms, and behavior. These products are not established treatments for ADHD or autism. Children require separate pediatric assessment.

Protocol overview: This proposed framework considers how mood, energy, anxiety, and sleep change before, during, and after menstruation. The goal of the clinical discussion is to match support to the symptom pattern rather than use an identical plan for everyone.

• Foundational components: Tro+ Blue and Tro+ Mune.
• Optional component for anxiety or irritability: Tro+ Calm, within the pathway for emotional lability and overactivation.
• Optional component for disrupted sleep: Tro+ Somna, within the pathway for trouble falling asleep, nighttime awakening, and poor sleep quality.

Clinical approach: Consider the relationship between symptoms and the menstrual cycle, symptoms outside that window, current PMDD treatment, and medication interactions. Prominent fatigue and disrupted sleep are also part of the assessment.

Cycle-related symptoms need individualized evaluation alongside existing PMDD treatment.

Protocol overview: Recent concussion and persistent post-concussion symptoms require different clinical assessments. This proposed product framework focuses on cellular energy, inflammatory signaling, sleep, cognition, and tolerance of activity.

• Core components: Tro+ Blue (methylene blue) and Tro+ Mune.
• Optional components: Blue Cannatine in the proposed pathway for brain fog or reduced stamina; Tro+ Calm for overactivation; and Tro+ Somna, with or without melatonin, for sleep disruption.

Clinical approach: Reassess symptoms and functioning as recovery changes. Watch for overstimulation, anxiety, and worsening sleep. Blue Cannatine contains nicotine and caffeine, which require specific safety review.

Important limit: A head injury needs medical evaluation; do not delay care to try a product. Medication and product decisions belong with the clinician overseeing recovery, alongside appropriate concussion care.

Protocol overview: Fatigue, stress, poor sleep, and cravings can overlap during addiction recovery. This proposed framework focuses on day-to-day capacity alongside psychological and behavioral recovery work.

• Tro+ Blue: The component in the proposed cellular-stability phase, focused on energy, clarity, and resilience.
• Tro+ Calm: The component in the proposed nervous-system regulation phase, focused on stress and overactivation.
• Tro+ Mune: The component in the proposed recovery and immune-support phase.
• Tro+ Somna: An optional component of the sleep-support pathway.

Beyond products: Explore sleep disorders, psychological stress and trauma, and other contributors to poor functioning. Ongoing reassessment includes whether product support remains appropriate as recovery progresses.

Important limit: This is not a detoxification or withdrawal-management plan and does not replace addiction care. Discuss cravings, sleep, relapse concerns, and all recovery medications with your treating clinician.

Protocol overview: This proposed framework addresses strength training, high-intensity intervals, and other short, demanding exercise. Its two product configurations are Blue Cannatine alone and Blue Cannatine with Tro+ Mune.

Components: Blue Cannatine contains methylene blue, CBD, caffeine, and nicotine. Cordycepin is the additional component discussed with Tro+ Mune.

Proposed roles: The framework explores cellular energy, alertness, fatigue, and exercise-related inflammatory signaling. Product order and individual tolerance are part of clinical review.

Before considering a product: Review the complete current product label, your medications, and your exercise goals with your clinician. Blue Cannatine contains caffeine and nicotine; nicotine is highly addictive. Product selection and any combination require an individualized assessment of potential benefits, interactions, and risks.

Protocol overview: This proposed framework addresses sustained activity such as zone 2 exercise, distance running, and longer events. It separates a foundation, an optional performance addition, and a recovery component.

• Foundation: Tro+ Blue, a methylene-blue product.
• Optional performance addition: Blue Cannatine, containing methylene blue, CBD, caffeine, and nicotine.
• Recovery component: Tro+ Calm, within the proposed post-exercise recovery pathway.

Proposed roles: Sustained cellular energy, mental drive during prolonged effort, and settling after exercise are the main areas of interest. Individual tolerance and the demands of the activity are part of clinical review.

Important limit: Nicotine is highly addictive, and sedating products may impair coordination. Discuss complete product labels, medication interactions, and exercise context with your clinician. Product combinations require an individualized assessment of potential benefits, interactions, and risks.